▎Edited by the WuXi AppTec content team
On January 3, Suzhou Ribo Life Science Co., Ltd. and Ribo International Research and Development Center jointly announced a research and development collaboration with Boehringer Ingelheim.Co-develop RNAi therapies for the treatment of nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH)。This collaboration has a potential value exceeding 2 billion US dollars.
It is estimated that there are over 440 million NASH patients globally, suffering from an inflammatory liver disease caused by the accumulation of fat in the liver. Over time, NASH can lead to liver fibrosis and tissue scarring, with many patients developing further complications such as cirrhosis, liver failure, or liver cancer. Currently, there are no approved drugs for the treatment of NASH, and patients urgently need new effective treatment options to prevent the progression of NASH and maintain or restore liver function.
Ribo's RIBO-GalSTAR technology platform is capable of developing RNAi therapies that specifically target pathogenic genes in hepatocytes, selectively inhibiting their mRNA.RNAi therapy has the potential to target undruggable targets that traditional drug molecules cannot address, achieving the goal of treating corresponding diseases.
According to the terms of the collaboration, in addition to receiving an upfront payment, Ribo will be entitled to receive milestone payments based on the conduct of clinical studies, regulatory submissions, and commercial successes, with a total amount exceeding 2 billion US dollars in this multi-target collaboration project.
▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.
[1] Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases. Retrieved January 3, 2024, from https://www.boehringer-ingelheim.com/partnering/human-health-partnering/partnership-new-liver-disease-treatments-riboDisclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.
Share，PointLike，In ViewFocusing on Global Biomedical Health Innovation
